# Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

> **NCT01353911** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 368 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Grazoprevir
- **DRUG:** Boceprevir
- **DRUG:** Placebo for Grazoprevir
- **DRUG:** Placebo for Boceprevir
- **DRUG:** Peg-interferon alfa-2b
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01353911
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-27
- **Primary completion:** 2013-01-20
- **Final completion:** 2015-03-10
- **Target enrollment:** 368 (ACTUAL)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01353911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01353911, "Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01353911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*